Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL502326 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL28381728 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL14574835 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL4191523 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL5011330 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL8166378 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL8166381 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL9400287 | 0.97 | CA4 (0.80) | CA4ALDH1A1 | |
| Citric Acid SCHEMBL23012792 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL20668544 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6228046-A | — | — | None | — | — | JP | disclosed |
| US-20240409547-A1 | Solid Forms of Upadacitinib | THE BANK OF NOVA SCOTIA (CA) | 2024-12-12 | — | — | US | disclosed |
| US-9260438-B2 | Solid forms of tofacitinib salts | APOTEX INC. (CA) | 2016-02-16 | — | — | US | disclosed |
| US-20150225406-A1 | SOLID FORMS OF TOFACITINIB SALTS | APOTEX INC. (CA) | 2015-08-13 | — | — | US | disclosed |
| US-8247363-B2 | Removing or preventing scale formation; using soluble magnesium salts; preinjection before evaporation | ECOLAB USA INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8143204-B2 | Removal or prevention scale formation; using soluble magnesium salts; preinjection before evaporation | ECOLAB USA INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090054290-A1 | MG++ CHEMISTRY AND METHOD FOR FOULING INHIBITION IN HEAT PROCESSING OF LIQUID FOODS AND INDUSTRIAL PROCESSES | ECOLAB INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008137796-A1 | MG++CHEMISTRY AND METHOD FOR FOULING INHIBITION IN HEAT PROCESSING OF LIQUID FOODS AND INDUSTRIAL PROCESSES | ECOLAB INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080274933-A1 | MG++ CHEMISTRY AND METHOD FOR FOULING INHIBITION IN HEAT PROCESSING OF LIQUID FOODS AND INDUSTRIAL PROCESSES | ECOLAB INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-6284927-B1 | FORMING ALCOHOL OR KETONE FROM DECOMPOSITION OF HYDROPEROXIDE | E. I. DU PONT NEMOURS AND COMPANY | 2001-09-04 | — | — | US | disclosed |
| EP-1012130-A2 | HYDROPEROXIDE DECOMPOSITION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0598824-B1 | METHOD FOR HYDROPHILIZING ABSORBENT FOAM MATERIALS | PROCTER & GAMBLE (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1998034894-A2 | HYDROPEROXIDE DECOMPOSITION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5352711-A | Treating with a surfactant and a solutions of a hydrated or hydratable salt; desolventizing | THE PROCTOR & GAMBLE COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| JP-H06228046-A | PRODUCTION OF MAGNESIUM HYDROGEN CITRATE PENTAHYDRATE | TOMITA SEIYAKU KK | 1994-08-16 | — | — | JP | disclosed |
| EP-0598824-A1 | METHOD FOR HYDROPHILIZING ABSORBENT FOAM MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993004113-A1 | METHOD FOR HYDROPHILIZING ABSORBENT FOAM MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225406-A1 | SOLID FORMS OF TOFACITINIB SALTS | JAK3, JAK2, JAK1 | CA4 420/4885ALDH1A1 4512/4885CASP1 947/4885 |
| US-20240409547-A1 | Solid Forms of Upadacitinib | AURKC, APC, CHUK | CA4 1700/4885ALDH1A1 1665/4885CASP1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.